Chinese Medicine Formula Huashibaidu Granule Early Treatment for Mild COVID-19 Patients: An Unblinded, Cluster-Randomized Clinical Trial
Chen Zhao,Li Li,Wei Yang,Wenliang Lv,Jian Wang,Jing Guo,Yu Dong,Nannan Shi,Cheng Lu,Zhiqiang Li,Zhan Shi,Renbo Chen,Ruili Huo,Qianzi Che,Yaxin Tian,Xinghua Xiang,Jian Wang,Junhui Zhou,Yongjun Bian,Suping Chen,Yang Chen,Yingying Chen,Xiaodong Cong,Guoju Dong,Lijie Hu,Jianxin Jiang,Luxing Leng,Bin Li,Dongxu Li,Hao Li,Jing Li,Wensheng Qi,Qing Miao,Huaxin Shi,Jiaheng Shi,Bing Wang,Gang Wang,Wei Wang,Yongyue Xian,Xiaolei Xie,Chunyan Xu,Ming Xu,Bei Yan,Jinliang Yang,Li Zhang,Zhenqi Zhou,Haoning Zhu,Yibai Xiong,Bin Liu,Luqi Huang
DOI: https://doi.org/10.3389/fmed.2021.696976
IF: 3.9
2021-09-16
Frontiers in Medicine
Abstract:Background: Previous research suggested that Chinese Medicine (CM) Formula Huashibaidu granule might shorten the disease course in coronavirus disease 2019 (COVID-19) patients. This research aimed to investigate the early treatment effect of Huashibaidu granule in well-managed patients with mild COVID-19. Methods: An unblinded cluster-randomized clinical trial was conducted at the Dongxihu FangCang hospital. Two cabins were randomly allocated to a CM or control group, with 204 mild COVID-19 participants in each cabin. All participants received conventional treatment over a 7 day period, while the ones in CM group were additionally given Huashibaidu granule 10 g twice daily. Participants were followed up to their clinical endpoint. The primary outcome was worsening symptoms before the clinical endpoint. The secondary outcomes were cure and discharge before the clinical endpoint and alleviation of composite symptoms after the 7 days of treatment. Results: All 408 participants were followed up to their clinical endpoint and included in statistical analysis. Baseline characteristics were comparable between the two groups ( P > 0.05). The number of worsening patients in the CM group was 5 (2.5%), and that in the control group was 16 (7.8%) with a significant difference between groups ( P = 0.014). Eight foreseeable mild adverse events occurred without statistical difference between groups ( P = 0.151). Conclusion: Seven days of early treatment with Huashibaidu granule reduced the likelihood of worsening symptoms in patients with mild COVID-19. Our study supports Huashibaidu granule as an active option for early treatment of mild COVID-19 in similar well-managed medical environments. Clinical Trial Registration: www.chictr.org.cn/showproj.aspx?proj=49408 , identifier: ChiCTR2000029763.
medicine, general & internal